Publications

5600 Results

Impact of Adjuvant Trastuzumab on Locoregional Failure Rates in the NCCTG N9831 (Alliance) Study

Authors
C Vargas;C Thorpe;A Dueck;K Tenner;E Perez;E Hwang;M Halyard;T Pisansky;N Davidson;S Martino;B Pockaj
Journal / Conference
Cancer Sep 15. doi: 10.1002/cncr.33154. Online ahead of print.
Year
2020
Research Committee(s)
Breast
PMC
PMID32931029
Study Number(s)
N9831

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Authors
A Fernandez-Martinez;J Kropf;D Hillman;M-Yin;J Parker;L Huebner;K Hoadley;J Sheperd;S Tolaney;NL Henry;C Dang;L Harris;D Berry;O Hahn;C Hudis;E Winer;A Partridge;C Perou;L Carey
Journal / Conference
Journal of Clinical Oncology Dec 10;38(35):4184-4193.
Year
2020
Research Committee(s)
Breast
PMID
PMID33095682
PMC
PMC7723687

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE VERSUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE FOR INITIAL THERAPY OF NEWLY DIAGNOSED MULTIPLE MYELOMA (ENDURANCE): A PHASE 3 TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E1A11)

Authors
S Kumar;S Jacobus;A Cohen;M Weiss;N Callander;A Singh;T Parker;A Menter;A Yang;B Parsons;P Kumar;P Kapoor;A Rosenberg;J Zonder;E Faber;S Lonial;P Richardson;R Orlowski;L Wagner;S Rajkumar
Journal / Conference
Lancet Oncology Oct;21(10):1317-1330
Year
2020
Research Committee(s)
Myeloma
PMID
PMID32866432
PMC
PMC7591827
Study Number(s)
CTSU/E1A11

A multicenter phase II trial (SWOG S1609, Cohort 51) of Ipilimumab and Nivolumab in metastatic or unresectable angiosarcoma: a sub-study of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Authors
M Wagner;M Othus;S Patel;C Ryan;A Sangal;B Powers;GT Budd;A Victor;C-T Hsueh;R Chugh;E Mayerson;M Plets;CD Blanke;H Streicher;YK Chae;R Kurzrock
Journal / Conference
Journal for ImmunoTherapy of Cancer Nov, 8 (Suppl 3) A843; Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-15, 2020, virtual), oral presentation
Year
2020
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Thyroid Tumor Cohort

Authors
YK Chae;M Othus;SP Patel;S Fenton;D Wang;C Rodriguez;A Onitilo;A Mattour;I Rybkin;J Hayward;C McLeod;H Chen;E Sharon;E Mayerson;CW Ryan;M Plets;CD Blanke;R Kurzrock
Journal / Conference
Journal for ImmunoTherapy of Cancer Nov, 8 (Suppl 3) A288; Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 10-15, 2020, virtual), poster
Year
2020
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol

Authors
M Redman;V Papadimitrakopoulou;K Minichiello;F Hirsch;P Mack;L Schwartz;E Vokes;S Ramalingam;N Leighl;J Bradley;J Miao;J Moon;L Highleyman;C Miwa;M LeBlanc;S Malik;V Miller;E Sigal;S Adam;D Wholley;C Sigman;B Smolich;CD Blanke;K Kelly;D Gandara;RS Herbst
Journal / Conference
Lancet Oncology Dec;21(12):1589-1601; Oct 27;. doi: 10.1016/S1470-2045(20)30475-7. [Epub ahead of print]
Year
2020
Research Committee(s)
Lung
PMID
PMID33125909
PMC
PMC8109255
Study Number(s)
S1400

Economic evaluations in NCI-sponsored network cancer clinical trials

Authors
VT Nghiem;R Vaidya;GH Lyman;DL Hershman;SD Ramsey;JM Unger
Journal / Conference
Value in Health Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9
Year
2020
Research Committee(s)
Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Leukemia, Lung, and Lymphoma
PMID
PMID33248521
PMC
PMC8262264
Study Number(s)
CTSU/E2100, E4494, JMA17, N9741, N9831, SWOG-8494 (INT-0036), SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891), SWOG-8794, SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12), SWOG-9031, SWOG-9412, SWOG-9509

Associations between genetically predicted blood protein biomarkers and pancreatic ductal adenocarcinoma risk

Authors
J Zhu;X Shu;X Guo;D Liu;J Bao;R Milne;G Giles;C Wu;M Du;E White;H Risch;N Malats;E Duell;P Goodman;D Li;P Bracci;V Katzke;E Jacobs;R Neale;S Gallinger;S Van Den Eeden;A Arslan;F Canzian;C Kooperberg;B Wolpin;L Beane-Freeman;G Scelo;K Visvanathan;C Haiman;H Yu;G Petersen;R Stolzenberg-Solomon;A Klein;L Amndadottir;Q Cai;J Long;X Shu;W Zheng
Journal / Conference
American Association for Cancer Research Annual Meeting 2020, #1200, poster
Year
2020
Research Committee(s)
Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
Study Number(s)
S0000

Dual Checkpoint Blockade in a Neuroendocrine Carcinoma with Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden [case report]

Authors
J Gong;D Adashek;D Frishberg;M Guan;V Placencio-Hickock;A Gangi;G Gresham;R Tuli;M Othus;YK Chae;R Kurzrock;A Hendifar
Journal / Conference
JCO Precision Oncology May 15;4:PO.18.00391
Year
2020
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID33215052
PMC
PMC7670562
Study Number(s)
S1609

Association of diet quality with survival among people with metastatic colorectal cancer: data from CALGB/SWOG 80405 (Alliance)

Authors
E Van Blarigan;S Zhang;F-S Ou;A Venook;K Ng;C Atreya;K Van Loon;D Niedzwiecki;E Giovannucci;E Wolfe;H-J Lenz;F Innocenti;B O'Neil;J Shaw;B Polite;H Hochster;J Atkins;R Goldberg;R Mayer;CD Blanke;E O'Reilly;C Fuchs;J Meyerhardt
Journal / Conference
JAMA Network Open Oct 1;3(10):e2023500
Year
2020
Research Committee(s)
Gastrointestinal
PMID
PMID33125497
PMC
PMC7599454
Study Number(s)
CTSU/C80405